German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
Injury concerns mount at La Cartuja
Barcelona’s emphatic 5-2 victory over Betis has been somewhat overshadowed by a growing injury list that threatens to derail...
President Trump used the antisemitic “Shylock” slur to defend endangered GOP Kansas Sen. Roger Marshall, a medical doctor who sued patients for unpaid medical...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
Injury concerns mount at La Cartuja
Barcelona’s emphatic 5-2 victory over Betis has been somewhat overshadowed by a growing injury list that threatens to derail...
President Trump used the antisemitic “Shylock” slur to defend endangered GOP Kansas Sen. Roger Marshall, a medical doctor who sued patients for unpaid medical...
Is the nightmare of injuries coming to an end?
Al-Nassr's injury crisis may finally be easing. Carlos Miguel, the Portuguese head of the Saudi club's...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
Neutrophils, the most abundant leukocytes in human blood, have multifaceted roles in health and disease. Here we assembled a single-cell atlas of human neutrophils...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
Rudolph Tanzi leads two efforts slated to get up to a combined $90 million from philanthropists, investors, and federal government.
Read the full story at...
German biotech advances a cancer therapy targeting PRAME with striking early results. Now it must prove the treatment works and can succeed commercially.
Read the...
